arrow
J

Jana Portnow

supportive care medicine
H指数:32
被引数:9,154

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating “Brain Permeability”: A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors

评估“血脑屏障通透性”:开发针对原发性和转移性脑肿瘤的治疗剂的关键问题

2026-03-120
OAAI
CTIM-07. A PHASE 1 STUDY OF INTRAVENTRICULARLY ADMINISTERED AUTOLOGOUS HER2-TARGETING CHIMERIC ANTIGEN RECEPTOR T CELLS (HER2-CAR T CELLS), WITH AND WITHOUT LYMPHODEPLETION, IN HER2-POSITIVE BREAST CANCER PATIENTS WITH RECURRENT BRAIN AND/OR LEPTOMENINGEAL METASTASES

CTIM-07。一项I期研究,评估经脑室内给药的自体HER2靶向嵌合抗原受体T细胞(HER2-CAR T细胞),在伴或不伴淋巴细胞清除的情况下,用于HER2阳性乳腺癌患者复发脑和/或软脑膜转移的疗效。

2025-11-110
OA
PHARMACOKINETIC ANALYSIS OF CARBOPLATIN AND FLUORESCEIN BRAIN PENETRATION AND PERMANENCE FOLLOWING ULTRASOUND-BASED BLOOD-BRAIN BARRIER OPENING ON GLIOBLASTOMA CLINICAL TRIAL
2024-11-110
PRE
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial (JUNE, 10.1038/s41591-024-02875-1, 2023)
2024-03-210
OAAI
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Il-13rα2靶向car-t细胞在复发性高级别胶质瘤中的局部区域递送: 1期试验

2024-03-0751
OAAI
Central Nervous System Cancers, Version 2.2022 Featured Updates to the NCCN Guidelines

中枢神经系统癌症,2.2022版特色更新NCCN指南

2023-01-0176
OA
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
2022-10-1294
OA
Central Nervous System Cancers Version 3.2020
2020-11-01310
OA